genprowebdirectory
News
Insights
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Supplement
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
News
Five Prime Therapeutics
Five Prime Eliminates 70 Jobs in Restructuring
News
CRISPR-Cas13 Developed as Combination Antiviral and Diagnostic System
Tech Exclusives
Blood Test to Diagnose Brain Cancer in Development
Neuroscience
Valium Soothes Best If Its Target Receptor Snuggles with Auxiliary Protein
News
UCB to Acquire Ra Pharma for $2.1B, Raising Rare Disease Presence
Insights
Commentary
Successfully Addressing the Challenges of Glycosylation
Brexit
Top 10 European Biopharma Clusters
Tech Exclusives
One-Stop-Shop Genome Editing Product Launched by Inscripta
October 2019 Vol. 39 No. 10
Better Living through Molecular Neuropharmacology
October 2019 Vol. 39 No. 10
CRISPR Dx May Help Nix Disease
A-Lists
Brexit
Top 10 European Biopharma Clusters
Insights
Top 10 U.S. Biopharma Clusters
Insights
10 Takeover Targets to Watch This Fall
Insights
What the Top 10 Biopharma CEOs Are Making
October 2019 Vol. 39 No. 10
Top 10 Companies Leveraging Gene Editing in 2019
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Five Prime Therapeutics
Five Prime Eliminates 70 Jobs in Restructuring
News
CRISPR-Cas13 Developed as Combination Antiviral and Diagnostic System
Tech Exclusives
Blood Test to Diagnose Brain Cancer in Development
Neuroscience
Valium Soothes Best If Its Target Receptor Snuggles with Auxiliary Protein
Magazine
All
Supplement
October 2019 Vol. 39 No. 10
Better Living through Molecular Neuropharmacology
October 2019 Vol. 39 No. 10
CRISPR Dx May Help Nix Disease
Tech Exclusives
Modular Bioprocessing Makes Adaptability a Snap
Tech Exclusives
A Nanomedicine Technology Sampler Pack
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Upcoming Webinars
A Cultured Life: Innovations in Spheroid and Organoid Models
Posters
Microfluidic Diffusional Sizing: A Novel Method for Characterizing Protein Interactions
Drug Discovery
Importance of mAb Discovery and Development in Immunotherapy
eBooks
Sample Preparation for Quality Control: Solutions for Optimized Workflows and Accurate…
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Home
Hematologic Conditions
Hematologic Conditions
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Hematologic Conditions
Chimerix Licenses Cantex’s CX-01 for AML after Promising Phase II Results
Hematologic Conditions
After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045
Hematologic Conditions
AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals
Hematologic Conditions
Harbour BioMed to Develop Kelun-Biotech’s Cancer Immunotherapy Candidate A167
Hematologic Conditions
Reversible Technique Developed for Stem Cell Expansion
Hematologic Conditions
Curcumin Shown to Inhibit DYRK2 and Reduce Cancer Burden
Hematologic Conditions
CRISPR Improves Red Blood Cell Transfusion Success
Hematologic Conditions
Model Wound System Created that Self Heals
Hematologic Conditions
Shire Hemophilia Candidate Using Xenetic Platform Falls Short in Trial
Hematologic Conditions
Nohla and UC Davis Ink Manufacturing Deal for Off-the-Shelf Donor Stem...
Hematologic Conditions
Novartis Acquires Selexys Pharmaceuticals
Hematologic Conditions
Takeda to Co-Develop Gencia’s MAGR Drugs in Up-to-$500M+ Partnership
Hematologic Conditions
Blood-Cleansing Biospleen Developed
Load more
Scroll Up
Please wait while you are redirected to the right page...
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Synthetic biologists at the University of Bristol have succeeded in generating laboratory-made red blood cells with rare blood group types. [Dr. Ashley Toye/University of Bristol]](https://www.genengnews.com/wp-content/uploads/2018/08/Apr30_2018_UnivBristol_GeneEditedRedBloodCells1901781571-324x160.jpg "CRISPR Improves Red Blood Cell Transfusion Success")
